United States

Fate Therapeutics, Memorial Sloan-Kettering partner on T-Cell Immunotherapies

Tuesday, September 13, 2016

Fate Therapeutics, a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, has announced a partnership with Memorial Sloan-Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Research and development activities under the multi-year collaboration will be led by Michel Sadelain, M.D., Ph.D., director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at Memorial Sloan-Kettering Cancer Center.

[Read More]

NCI embraces scientific road map to achieve Cancer Moonshot goals

Tuesday, September 13, 2016

National Cancer Institute (NCI) Acting Director Douglas Lowy, M.D., has accepted the recommendations of a Blue Ribbon Panel (BRP) on 10 scientific approaches most likely to make a decade’s worth of progress against cancer in five years under the Cancer Moonshot. The report was presented by the BRP to the National Cancer Advisory Board (NCAB), and it was subsequently considered and accepted by the NCAB with revisions that reflect the NCAB’s discussion. An overview of the report was published today in the journal Science.

[Read More]

Federal prize competition seeks innovative ideas to combat antimicrobial resistance

Tuesday, September 13, 2016

A federal prize competition launched calling for innovative ideas for rapid, point-of-care laboratory diagnostic tests to combat the development and spread of drug resistant bacteria, a rising public health threat. Antibiotic resistant bacteria cause at least 2 million infections and 23,000 deaths each year in the U.S., according to the Centers for Disease Control and Prevention.

[Read More]

NIH award expands landmark Alzheimer’s biomarker study

Tuesday, September 13, 2016

The Alzheimer’s Disease Neuroimaging Initiative (ADNI)—the long-running NIH-supported study investigating brain and fluid biomarkers of the disease—enters a new phase of discovery with the launch of ADNI3. With the recent NIH award of approximately $40 million over the next five years—coupled with anticipated private sector contributions of $20 million through the Foundation for the National Institutes of Health (FNIH)—ADNI3 will use cutting-edge technologies in brain imaging as it recruits hundreds of new volunteers. Expansion of the groundbreaking study, now in its 12th year, will further develop ways to speed clinical trials by providing researchers the biomarkers needed to detect the onset and track the progression of Alzheimer’s disease.

[Read More]

St. Jude Medical sues Muddy Waters and MedSec

Monday, September 12, 2016

St. Jude Medical, a global medical device company, has filed a lawsuit against Muddy Waters Consulting, Muddy Waters Capital, MedSec Holdings, MedSec and three individual defendants who are principals in these firms, for false statements, false advertising, conspiracy and the related manipulation of the public markets in connection with St. Jude Medical’s implantable cardiac management devices.

[Read More]

Woodlands Medical Specialists joins The US Oncology Network

Thursday, September 8, 2016

Woodlands Medical Specialists, a physician-owned multi-specialty outpatient clinic serving Florida’s Panhandle region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for large practices such as Woodlands navigating today’s challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry leader in solutions that empower the community patient care delivery system to advance the science, technology and quality of care. The agreement unites two like-minded organizations with a vision of keeping independent physician groups strong and viable, while sharing a common goal of improving patient health.

[Read More]

GlobalMed named Arizona Bioscience Company of the Year

Thursday, September 8, 2016

The Arizona Bioindustry Association (AZBio) will honor GlobalMed as the Arizona Bioscience Company of the Year at the 2016 AZBio Awards on September 21, 2016. Hundreds of Arizona life science and business leaders as well as guests from across the country will be on hand at the Phoenix Convention Center to recognize GlobalMed for the many ways that the team, the company and their technology are making life better for people here in Arizona and around the world.

[Read More]